Champions Oncology (CSBR) 10-Q 13 Dec 13 2014 Q2 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	6 Months Ended
	Oct. 31, 2013	Nov. 30, 2013
Document Information [Line Items]	'	'
Entity Registrant Name	'CHAMPIONS ONCOLOGY, INC.	'
Entity Central Index Key	'0000771856	'
Current Fiscal Year End Date	'--04-30	'
Entity Filer Category	'Smaller Reporting Company	'
Trading Symbol	'CSBR	'
Entity Common Stock, Shares Outstanding	'	66,867,100
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Oct-13	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Oct. 31, 2013	Apr. 30, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$7,572	$9,561
Accounts receivable, net	1,462	500
Prepaid expenses and other current assets	219	315
Total current assets	9,253	10,376
Restricted cash	193	192
Property and equipment, net	387	414
Goodwill	669	669
Total assets	10,502	11,651
Current liabilities:	'	'
Accounts payable	982	1,204
Accrued liabilities	329	611
Deferred revenue	1,958	1,114
Total current liabilities	3,269	2,929
Warrant liability	3,094	1,046
Total liabilities	6,363	3,975
Commitments and contingencies	'	'
Redeemable common stock; $0.001 par value; 31,133,333 contingently puttable common shares outstanding as of October 31, 2013 and April 30, 2013	16,882	16,882
Stockholders' equity:	'	'
Common stock, $.001 par value; 125,000,000 shares authorized, including redeemable common stock, 38,970,003 and 38,955,003 shares issued and 35,733,767 and 35,718,767 shares outstanding as of October 31, 2013 and April 30, 2013, respectively	39	39
Treasury stock, at cost, 3,236,236 common shares as of October 31, 2013 and April 30, 2013	-1,252	-1,252
Additional paid-in capital	24,617	23,580
Accumulated deficit	-36,023	-31,473
Accumulated other comprehensive loss	-124	-100
Total stockholders' deficit	-12,743	-9,206
Total liabilities, redeemable common stock and stockholders' deficit	$10,502	$11,651

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Oct. 31, 2013	Apr. 30, 2013
Redeemable common stock, par value (in dollars per share)	$0.00	$0.00
Redeemable common stock, shares outstanding	31,133,333	31,133,333
Common stock, par value (in dollars per share)	$0.00	$0.00
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	38,970,003	38,955,003
Common stock, shares outstanding	35,733,767	35,718,767
Treasury stock, shares	3,236,236	3,236,236

UNAUDITED_CONDENSED_CONSOLIDAT

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Operating revenue:	'	'	'	'
Personalized oncology solutions	$623	$459	$1,245	$1,377
Translational oncology solutions	1,760	999	4,158	2,187
Total operating revenue	2,383	1,458	5,403	3,564
Costs and operating expenses:	'	'	'	'
Cost of personalized oncology solutions	732	582	1,525	1,354
Cost of translational oncology solutions	698	475	1,576	1,174
Research and development	677	436	1,079	823
Sales and marketing	698	680	1,340	1,389
General and administrative	1,279	1,201	2,355	2,340
Total costs and operating expenses	4,084	3,374	7,875	7,080
Loss from operations	-1,701	-1,916	-2,472	-3,516
Other (expense) income:	'	'	'	'
Change in fair value of warrant liability	-585	-52	-2,048	233
Other (expense)	-29	-5	-30	-10
Total other (expense) income	-614	-57	-2,078	223
Loss before provision for income taxes	-2,315	-1,973	-4,550	-3,293
Provision for income taxes	3	1	6	4
Net loss	($2,318)	($1,974)	($4,556)	($3,297)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)	($0.03)	($0.04)	($0.07)	($0.07)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)	66,863,147	47,079,000	66,857,630	47,073,000

UNAUDITED_CONDENSED_CONSOLIDAT1

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Net loss	($2,318)	($1,974)	($4,556)	($3,297)
Foreign currency translation adjustment	-12	2	-24	27
Comprehensive loss	($2,330)	($1,972)	($4,580)	($3,270)

UNAUDITED_CONDENSED_CONSOLIDAT2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012
Operating activities:	'	'
Net loss	($4,556)	($3,297)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Stock-based compensation expense	1,028	1,364
Depreciation expense	102	103
Change in fair value of warrant liability	2,048	-233
Changes in operating assets and liabilities:	'	'
Accounts receivable	-962	-43
Prepaid expenses, deposits and other	96	110
Restricted cash	-1	0
Accounts payable	-220	-467
Accrued liabilities	-282	-111
Deferred revenue	845	20
Net cash used in operating activities	-1,902	-2,554
Investing activities:	'	'
Purchase of property and equipment	-76	-28
Net cash provided by investing activities	-76	-28
Financing activities:	'	'
Proceeds from exercise of stock options	9	0
Net cash used in financing activities	9	0
Exchange rate effect on cash and cash equivalents	-20	27
Decrease in cash and cash equivalents	-1,989	-2,555
Cash and cash equivalents, beginning of period	9,561	4,716
Cash and cash equivalents, end of period	$7,572	$2,161

Organization_Use_of_Estimates_

Organization, Use of Estimates and Basis of Presentation	6 Months Ended
	Oct. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	'
	Note 1.  Organization, Use of Estimates and Basis of Presentation
	Champions Oncology, Inc. or the Company, is engaged in the development of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care, based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two customer groups:
		·	Our Personalized Oncology Solutions, or POS, business, which provides services to physicians and patients looking for information to help guide the development of personalized treatment plans.
		·	Our Translational Oncology Solutions, or TOS, business, which provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development that will lower costs and increase the speed of developing new drugs, as well as increase the adoption of existing drugs.
	The Company has three operating subsidiaries: Champions Oncology (Israel), Limited, Champions Biotechnology U.K., Limited and Champions Oncology Singapore, PTE LTD. To date, there have been no material revenues earned by these subsidiaries.
	The financial statements of the Company’s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated into the U.S. dollar for the Company’s consolidated financial statements for each period being presented. Translation gains and losses are recognized as a component of accumulated other comprehensive loss in the accompanying consolidated balance sheets. Transaction gains and losses are recognized in earnings in other (expense) income. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations.
	These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission or the SEC. All significant intercompany transactions and accounts have been eliminated. All figures are presented in thousands of U.S. dollars, except share data, or except where expressly stated otherwise. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States or GAAP has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2013, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state our financial position, results of operations and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2013.
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the year.  Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the year, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method.  Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable.  Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied or would be satisfied if the end of the reporting period were the end of the contingency period.  Due to the net losses for the three and six months ended October 31, 2013 and 2012, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.
	The following table reflects the total potential share-based instruments outstanding at October 31, 2013 and 2012 that could have an effect on the future computation of dilution per common share:
			October 31,
			2013	2012
	Stock options		15,473,955	14,643,955
	Warrants		3,276,667	1,416,667
	Total common stock equivalents		18,750,622	16,060,622

Property_and_Equipment

Property and Equipment	6 Months Ended
	Oct. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment Disclosure [Text Block]	'
	Note 2. Property and Equipment
	Property and equipment is recorded at cost and consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):
		October 31,		April 30,
		2013		2013
		(unaudited)
	Furniture and fixtures	$	59	$	59
	Computer equipment and software		620		549
	Laboratory equipment		185		179
	Leasehold improvements		2		2
	Total property and equipment		866		789
	Less: Accumulated depreciation		-479		-375
	Property and equipment, net	$	387	$	414
	Depreciation expense was $53,000 and $49,000 for the three months ended October 31, 2013 and 2012, respectively, and $102,000 and $103,000 for the six months ended October 31, 2013 and 2012, respectively.

ShareBased_Payments

Share-Based Payments	6 Months Ended
	Oct. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 3. Share-Based Payments
	The Company has in place a 2010 Equity Incentive Plan and a 2008 Equity Incentive Plan. In general, these plans provide for stock-based compensation in the form of (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards.
	Stock-based compensation in the amount of $476,000 and $624,000 was recognized for the three months ended October 31, 2013 and 2012, respectively, and $1,028,000 and $1,364,000 for the six months ended October 31, 2013 and 2012, respectively.  Stock-based compensation expense was recognized as follows (in thousands):
		Three Months Ended						Six Months Ended
		October 31,						October 31,
		2013			2012			2013			2012
	General and administrative	$	401		$	550		$	820		$	1,119
	Sales and marketing		63			61			126			143
	Research and development		3			3			16			29
	TOS cost of sales		3			4			11			12
	POS cost of sales		6			6			55			61
	Total stock-based compensation expense	$	476		$	624		$	1,028		$	1,364
	Stock Option Grants
	Black-Scholes assumptions used to calculate the fair value of options granted during the three and six months ended October 31, 2013 and 2012 were as follows (in thousands):
		Three Months Ended				Six Months Ended
		October 31,				October 31,
		2013		2012		2013		2012
	Expected term in years	6		6		6		6
	Risk-free interest rates	1.13% - 2.41%		0.90%		1.13% - 2.41%		0.8% - 0.9%
	Volatility	97.9% - 101.4%		99% - 100%		97.9% - 101.4%		99% - 100%
	Dividend yield	0%		0%		0%		0%
	The weighted average fair value of stock options granted during the three months ended October 31, 2013 and 2012 was $1.06 and $ 0.26, respectively. The weighted average fair value of stock options granted during the six  months ended October 31, 2013 and 2012 was $0.94 and $0.52, respectively. The Company’s stock options activity for the six months ended October 31, 2013 is as follows:
											Weighted
								Weighted			Average
				Directors				Average			Remaining		Aggregate
		Non-		and				Exercise			Contractual		Intrinsic
		Employees		Employees		Total		Price			Life (Years)		Value
	Outstanding, May 1, 2013	765,000		13,125,205		13,890,205		$	0.85		7		$	89,000
	Granted	-		1,645,000		1,645,000			1.18		9.8			237,000
	Exercised	-		-15,000		-15,000			0.62
	Forfeited	-		-20,000		-20,000			0.5
	Expired	-		-26,250		-26,250			0.75
	Outstanding, October 31, 2013	765,000		14,708,955		15,473,955			0.89		6.8			6,290,000
	Vested and expected to
	vest as of October 31, 2013	765,000		14,708,955		15,473,955			0.89		6.8			6,290,000
	Exercisable as of
	31-Oct-13	514,792		13,014,370		13,529,162			0.85		6.5			2,703,000
	Included in the balances outstanding in the table above are 10,000,000 options granted to the Company’s Chief Executive Officer and its President at the time of commencement of their employment in fiscal 2011, of which 5,000,000 contain only service-based vesting provisions and 5,000,000 contain both service and performance-based vesting provisions.  The service-based provisions of these options provide for vesting to occur monthly over a period of three years.  The performance-based conditions, which had to be met prior to vesting to occur included: (i) closing of one or more financings of the Company in the aggregate amount of at least $5,000,000; (ii) bringing in new Company management; (iii) launching of personalized medicine (oncology) business; and (iv) commencing implementation of the Company’s business plan.   The service-based options, like all of the Company’s service-based options, are expensed on a straight-line basis.  Since the straight-line method is not available for performance or market-based share-based payments, the 5,000,000 performance-based options are being expensed on an accelerated basis.  The Company’s Board of Directors determined that in April 2011 each of the performance conditions under the awards were met.
	Subsequent to October 31, 2013, but prior to the issuance of this Form 10Q, the company granted approximately 6.4 million stock options to certain employees at a weighted average exercise price of $1.23.
	Restricted Stock Grants
	A summary of the activity related to restricted stock grants is as follows (in thousands):
				Weighted
				Average Grant
				Date Fair Value
		Shares		Per Share
	Nonvested as of May 1, 2013	50,000		$	0.3
	Granted	-			-
	Vested	-50,000			0.3
	Forfeited	-			-
	Expired	-			-
	Nonvested as of October 31, 2013	-			-
	The aggregate fair value of shares vested during the six months ended October 31, 2013 and 2012 was $7,500 and $11,000, respectively.
	Stock Purchase Warrants
	As of October 31, 2013 and April 30, 2013, the Company had warrants outstanding for the purchase of 3,276,667 shares of its common stock, all of which were exercisable. Of these warrants, 1,266,667 were issued in connection with the April 2011 Private Placement and 1,860,000 were issued in connection with the January 2013 Private Placement and are accounted for as liabilities as further discussed in Note 4. The remaining 150,000 warrants are accounted for as equity instruments and expire on July 31, 2014. Activity related to these warrants, which expire at various dates through April 2016, is summarized as follows (dollars in thousands):
							Weighted
				Weighted			Average
		Number		Average			Remaining		Aggregate
		of		Exercise			Contractual		Intrinsic
		Shares		Price			Life (Years)		Value
	Outstanding, May 1, 2013	3,276,667		$	0.61		3.9		$	-
	Granted	-			-		-			-
	Exercised	-			-		-			-
	Expired	-			-		-			-
Outstanding, October 31, 2013	3,276,667		$	0.61		3.4		$	2,215,967

Redeemable_Common_Stock_and_St

Redeemable Common Stock and Stock Purchase Warrants	6 Months Ended
	Oct. 31, 2013
Redeemable Common Stock and Stock Purchase Warrant [Abstract]	'
Redeemable Common Stock and Stock Purchase Warrant [Text Block]	'
	Note 4. Redeemable Common Stock and Stock Purchase Warrants
	On January 28, 2013, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 18,600,000 shares of the Company’s Common Stock at a purchase price of $0.50 per share, for aggregate proceeds of $9.3 million (net proceeds of $9.1 million due to issuance costs), $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed on January 28, 2013. As part of this transaction, the Company also issued warrants to purchase an aggregate 1,860,000 shares of Common Stock at an exercise price of $0.66 per share. These warrants expire five years after the closing date. The Company also entered into an Amended and Restated Registration Rights Agreement on January 28, 2013 that provided certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors will have the right to require the Company to redeem the purchased common shares held by all of the investors  for cash of $0.50 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. This put option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement. The January 2013 Private Placement investors also have certain participation rights with respect to future financings of the Company. The terms of the January 2013 Private Placement resulted in the issuance of an additional 1,064,658 common shares to the investors of the April 2011 Private Placement under the anti-dilution protections granted such investors, which are discussed below.
	On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 12,533,333 shares of the Company’s Common Stock at a purchase price of $0.75 per share, for aggregate proceeds of $9.4 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed April 4, 2011 . As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667 shares of Common Stock at an exercise price of $0.90 per share. These warrants expire five years after the closing date. The Securities Purchase Agreement governing the April 2011 Private Placement contains certain anti-dilution protections for the investors. The Amended and Restated Registration Rights Agreement referenced above provides certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors have the right to require the Company to redeem the purchased common shares held by all of the investors  for cash for $0.75 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. This put option  will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement.
	Due to the April 2011 and the January 2013 put option described above, the Company has accounted for the Common Stock for the April 2011 Private Placement and January 2013 Private Placement as temporary equity, which is reflected under the caption “redeemable common stock” on the accompanying consolidated balance sheets. The total amount allocated to the redeemable common stock was $8.8 million for the January 2013 Private Placement and $8.2 million for the April 2011 Private Placement. For the January 2013 Private Placement, this allocation is equal to the total proceeds of $9.3 million less the amount allocated to the warrants of $0.4 million and is also net of the direct and incremental costs associated with the January 2013 Private Placement of $0.2 million. For the April 2011 Private Placement, this allocation is equal to the total proceeds of $9.4 million, less the amount allocated to the warrants of $0.9 million and is also net of direct and incremental costs associated with the April 2011 Private Placement of $0.3 million.
	The warrants issued in connection with both the April 2011 Private Placement and January 2013 Private Placement contain certain exercise price antildilution provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the April 2011 Private Placement Securities Purchase Agreement and January 2013 Private Placement Securities Purchase Agreement). These exercise price antidilution provisions resulted in a downward adjustment to the exercise price of the warrants issued in the April 2011 Private Placement from $0.90 to $0.50.
	The Company has accounted for the warrants issued in connection with the April 2011 Private Placement and January 2013 Private Placement as a liability based on the exercise price reset provisions described above. This liability, which is recorded at fair value on the accompanying consolidated balance sheets, totaled $0.8 million at the time of the close of the January 2013 Private Placement Agreement. As of October 31, 2013 and April 30, 2013, the fair value of these warrants was $3.09 million and $1.05 million, respectively. The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company’s consolidated statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:
		October 31,	April 30,
		2013	2013
	Expected term in years	2.4 & 4.2	2.9 & 4.7
	Risk-free interest rates	0.5% & 1.1%	0.30%
	Volatility	91% & 107%	95% & 98%
	Dividend yield	0%	0%
	In addition to the assumptions above, the Company also takes into consideration whether or not the Company would participate in another round of financing and if that financing is registered or not and what that stock price would be for the financing at that time. The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants.
	The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants for both the April 2011 Private Placement and January 2013 Private Placement. These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period. If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Amended Restated Registration Rights Agreement, exists. These penalties are subject to a 10% limit of the aggregate purchase price paid by the investors. The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement ranges from $50,000 to $130,000 for each 30-day period in which a registration default exists; however, as of October 31, 2013 and April 30, 2013, and through the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Oct. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 5. Related Party Transactions
	Related party transactions include transactions between the Company and its shareholders, management, or affiliates.  The following transactions were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.
	Consulting Services
	During the six months ended October 31, 2012, the Company paid one of its directors and former Chief Executive Officer$30,000 in consulting fees.  During the six months ended October 31, 2013 and 2012, the Company paid certain members of its Board of Directors $75,000 and $73,000, respectively, for consulting services unrelated to their duties as board members. During the six months ended October 31, 2012, the Company paid a substantial stockholder and former member of its Board of Directors $3,000 for consulting services. All of the amounts paid to these related parties have been expensed.

Commitments_and_Contingencies

Commitments and Contingencies	6 Months Ended
	Oct. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	Note 6. Commitments and Contingencies
	Operating Leases
	As of October 31, 2013, we lease the following facilities under operating lease agreements:
		⋅	One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. The lease expires in April 2014. The Company recognized $34,000 of rental costs relative to this lease for each of the six months ended October 31, 2013 and 2012.
		⋅	855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducts operations related to its primary service offerings. This lease expires in April 2014. The Company recognized $43,000 and $33,000 of rental costs relative to this lease for the six months ended October 31, 2013 and 2012, respectively.
		⋅	17 Hatidhar Street, Ra’anana, Israel, which served as office headquarters for Champions Oncology, Israel. The Company recognized $6,000 and $14,000 of rental costs relative to this lease for the six months ended October 31, 2013 and 2012, respectively. This lease expired in July 2013 and was not renewed.
		⋅	57 Mohamed Sultan Road, Singapore, which serves as office headquarters for Champions Oncology, Singapore. The lease expires in January 2014. We incurred $3,000 and nil of rental expense for the six months ended October 31, 2013 and 2012, respectively.
	Legal Matters
	The Company is not currently party to any material legal matters to its knowledge. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations.
	Registration Payment Arrangements
	The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the April 2011 Private Placement and January 2013 Private Placement and is discussed more fully in Note 4. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company’s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company does not believe it is probable that penalty payments will be made for the Amended and Restated Registration Rights Agreement discussed in Note 4 and, accordingly, has not accrued for such potential penalties as of October 31, 2013 and April 30, 2013.

Licensing_Agreements

Licensing Agreements	6 Months Ended
	Oct. 31, 2013
Licensing Agreements [Abstract]	'
Licensing Agreements Disclosure [Text Block]	'
	Note 7. Licensing Agreements
	In February 2010, the Company entered into an exclusive option agreement with a Canadian company. The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast, and lung cancer through April 2011. During the option year, the Company performed various TumorGraft tests on the nanoparticle compound. In March 2011, the Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. On the first anniversary of the agreement (March 2012), an additional license fee of $45,000 (Canadian) became due, which was recognized as a liability as of April 30, 2012 and was satisfied during the year ended April 30, 2013. Commencing with the second anniversary of the agreement (March 2013), the Company is obligated to pay a minimum annual royalty of $10,000 (Canadian), unless the agreement were terminated by either party in advance of the anniversary date. Under the terms of the license agreement, the Company will be required to pay up to $3.0 million in development milestones, if achieved. The Company does not believe development milestones will be achieved within the next 12 months. Upon commercialization, the Company would also be required to make royalty and sales milestone payments based upon revenues. As of April 30, 2013 the Company had accrued for the March 2013 annual royalty payment of $10,000 (Canadian) and was satisfied during the quarter ended July 31, 2013.

Cephalon_and_Teva_Agreement

Cephalon and Teva Agreement	6 Months Ended
	Oct. 31, 2013
Cephalon and Teva Agreement [Abstract]	'
Cephalon and Teva Agreement [Text Block]	'
	Note 8. Cephalon and Teva Agreement
	On March 16, 2011, the Company entered into an agreement with Cephalon, Inc., or Cephalon,, a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., or Teva, pursuant to which the Company agreed to conduct TumorGraft studies on two proprietary chemical compounds provided by Cephalon to determine the activity or response of these compounds in potential clinical indications. Under certain conditions, Cephalon reserved the right to exercise and pay a one-time fee of in lieu of the milestone or royalty payments, which are $460,000 for one compound and $880,000 for the other compound.
	On November 30, 2012, Cephalon exercised the option to pay this one-time fee of $880,000 to the Company, in lieu of any future milestone or royalty payments, for one compound tested under the agreement described above. Written notice was provided to the Company on December 3, 2012 and payment was received on December 19, 2012. This fee has been recognized as revenue during the third quarter of fiscal 2013.
	During fiscal 2013, the agreement with Cephalon was amended to perform additional services for an increased fee of $277,000. As models, along with required reports, are delivered, revenue is recognized on a performance basis in accordance with the Company’s revenue recognition policies. Revenues of $133,000 and $237,000 were recognized during the six months ended October 31, 2013 and 2012, respectively, which are independent of the $880,000 noted above.
	On July 30, 2013, the Company entered into an agreement with Teva pursuant to which the Company agreed to conduct TumorGraft studies on multiple proprietary chemical compounds provided by Teva to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Teva agreed to, pay an upfront payment and, under certain conditions, pay the Company various amounts upon achieving certain milestones, based on the performance of the compounds in preclinical testing and dependent upon testing the compound in clinical settings and obtaining FDA approval. In addition, Teva agrees to pay the Company royalties on any commercialized products developed under the agreement. This agreement terminates the collaborative agreement noted above between Cephalon and the Company.

Fair_Value

Fair Value	6 Months Ended
	Oct. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	Note 9. Fair Value
	The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable, and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:
	⋅      Level one — Quoted market prices in active markets for identical assets or liabilities;
	⋅      Level two — Inputs other than level one inputs that are either directly or indirectly observable; and
	⋅      Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.
	Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in connection with private placements of the Company’s securities that are discussed more fully in Note 4. As of October 31, 2013 and April 30, 2013, these warrants had an estimated fair value of $3,094,000 and $1,046,000, respectively, which was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis as of October 31, 2013 and April 30, 2013 or during the six months ended October 31, 2013 and 2012.
	The following table presents information about our warrant liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of October 31, 2013 (in thousands):
	Balance, May 1, 2013	$	-1,046
	Transfers to (from) Level 3		-
	Total gains (losses) included in earnings		-2,048
	Purchases, issuances and settlements, net		-
	Balance, October 31, 2013	$	-3,094

Business_Segment_Information

Business Segment Information	6 Months Ended
	Oct. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 10. Business Segment Information
	The Company operates in two segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual financial statements for the year ended April 30, 2013, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
	Three Months Ended October 31, 2013	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Corporate
		Solutions		Solutions		Overhead
		(POS)		(TOS)
	Net revenue	$	623	$	1,760	$	-	$	2,383
	Direct cost of services		-726		-696		-		-1,422
	Sales and marketing costs		-423		-213		-		-636
	Other operating expenses		-		-673		-877		-1,550
	Stock- based compensation expense (1)		-				-476		-476
	Segment profit (loss)	$	-526	$	178	$	-1,353	$	-1,701
	Three Months Ended October 31, 2012	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Corporate
		Solutions		Solutions		Overhead
		(POS)		(TOS)
	Net revenue	$	459	$	999	$	-	$	1,458
	Direct cost of services		-576		-471		-		-1,047
	Sales and marketing costs		-378		-241		-		-619
	Other operating expenses		-		-433		-651		-1,084
	Stock- based compensation expense (1)		-		-		-624		-624
	Segment profit (loss)	$	-495	$	-146	$	-1,275	$	-1,916
	Six Months Ended October 31, 2013	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Corporate
		Solutions		Solutions		Overhead
		(POS)		(TOS)
	Net revenue	$	1,245	$	4,158	$	-	$	5,403
	Direct cost of services		-1,470		-1,566		-		-3,036
	Sales and marketing costs		-754		-460		-		-1,214
	Other operating expenses		-		-1,063		-1,534		-2,597
	Stock- based compensation expense (1)		-		-		-1,028		-1,028
	Segment profit (loss)	$	-979	$	1,069	$	-2,562	$	-2,472
	Six Months Ended October 31, 2012	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Corporate
		Solutions		Solutions		Overhead
		(POS)		(TOS)
	Net revenue	$	1,377	$	2,187	$	-	$	3,564
	Direct cost of services		-1,293		-1,162		-		-2,455
	Sales and marketing costs		-814		-432		-		-1,246
	Other operating expenses		-		-794		-1,221		-2,015
	Stock- based compensation expense (1)		-		-		-1,364		-1,364
	Segment profit (loss)	$	-730	$	-201	$	-2,585	$	-3,516
	(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.
	All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.

Subsequent_Events

Subsequent Events	6 Months Ended
	Oct. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	Note 11. Subsequent Events
	On December 6, 2013, the Company entered into a licensing agreement with Pfizer Inc., pursuant to which the Pfizer acquired a license to utilize a portion of the Company’s TumorGraft technology platform for its studies. In addition, the Company and Pfizer will seek opportunities for further platform development and research collaboration. In consideration for the license, Pfizer will pay an aggregate payment $1,875,000, of which $937,500 is due upon execution of the agreement and the remaining $937,500 will be paid upon successful delivery.

Organization_Use_of_Estimates_1

Organization, Use of Estimates and Basis of Presentation (Tables)	6 Months Ended
	Oct. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
	The following table reflects the total potential share-based instruments outstanding at October 31, 2013 and 2012 that could have an effect on the future computation of dilution per common share:
		October 31,
		2013	2012
	Stock options	15,473,955	14,643,955
	Warrants	3,276,667	1,416,667
	Total common stock equivalents	18,750,622	16,060,622

Property_and_Equipment_Tables

Property and Equipment (Tables)	6 Months Ended
	Oct. 31, 2013
Property, Plant and Equipment [Abstract]	'
Property, Plant and Equipment [Table Text Block]	'
	Property and equipment consisted of the following (in thousands):
		October 31,		April 30,
		2013		2013
		(unaudited)
	Furniture and fixtures	$	59	$	59
	Computer equipment and software		620		549
	Laboratory equipment		185		179
	Leasehold improvements		2		2
	Total property and equipment		866		789
	Less: Accumulated depreciation		-479		-375
	Property and equipment, net	$	387	$	414

ShareBased_Payments_Tables

Share-Based Payments (Tables)	6 Months Ended
	Oct. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	Stock-based compensation expense was recognized as follows (in thousands):
		Three Months Ended						Six Months Ended
		October 31,						October 31,
		2013			2012			2013			2012
	General and administrative	$	401		$	550		$	820		$	1,119
	Sales and marketing		63			61			126			143
	Research and development		3			3			16			29
	TOS cost of sales		3			4			11			12
	POS cost of sales		6			6			55			61
	Total stock-based compensation expense	$	476		$	624		$	1,028		$	1,364
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	Black-Scholes assumptions used to calculate the fair value of options granted during the three and six months ended October 31, 2013 and 2012 were as follows (in thousands):
		Three Months Ended				Six Months Ended
		October 31,				October 31,
		2013		2012		2013		2012
	Expected term in years	6		6		6		6
	Risk-free interest rates	1.13% - 2.41%		0.90%		1.13% - 2.41%		0.8% - 0.9%
	Volatility	97.9% - 101.4%		99% - 100%		97.9% - 101.4%		99% - 100%
	Dividend yield	0%		0%		0%		0%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The Company’s stock options activity for the six months ended October 31, 2013 is as follows:
											Weighted
								Weighted			Average
				Directors				Average			Remaining		Aggregate
		Non-		and				Exercise			Contractual		Intrinsic
		Employees		Employees		Total		Price			Life (Years)		Value
	Outstanding, May 1, 2013	765,000		13,125,205		13,890,205		$	0.85		7		$	89,000
	Granted	-		1,645,000		1,645,000			1.18		9.8			237,000
	Exercised	-		-15,000		-15,000			0.62
	Forfeited	-		-20,000		-20,000			0.5
	Expired	-		-26,250		-26,250			0.75
	Outstanding, October 31, 2013	765,000		14,708,955		15,473,955			0.89		6.8			6,290,000
	Vested and expected to
	vest as of October 31, 2013	765,000		14,708,955		15,473,955			0.89		6.8			6,290,000
	Exercisable as of
	31-Oct-13	514,792		13,014,370		13,529,162			0.85		6.5			2,703,000
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	'
	A summary of the activity related to restricted stock grants is as follows (in thousands):
				Weighted
				Average Grant
				Date Fair Value
		Shares		Per Share
	Nonvested as of May 1, 2013	50,000		$	0.3
	Granted	-			-
	Vested	-50,000			0.3
	Forfeited	-			-
	Expired	-			-
	Nonvested as of October 31, 2013	-			-
Schedule Of Share Based Compensation Warrants Activity [Table Text Block]	'
	Activity related to these warrants, which expire at various dates through April 2016, is summarized as follows (dollars in thousands):
							Weighted
				Weighted			Average
		Number		Average			Remaining		Aggregate
		of		Exercise			Contractual		Intrinsic
		Shares		Price			Life (Years)		Value
	Outstanding, May 1, 2013	3,276,667		$	0.61		3.9		$	-
	Granted	-			-		-			-
	Exercised	-			-		-			-
	Expired	-			-		-			-
	Outstanding, October 31, 2013	3,276,667		$	0.61		3.4		$	2,215,967

Redeemable_Common_Stock_and_St1

Redeemable Common Stock and Stock Purchase Warrants (Tables)	6 Months Ended
	Oct. 31, 2013
Redeemable Common Stock and Stock Purchase Warrant [Abstract]	'
Schedule of Share-based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	'
	Assumptions used to calculate the fair value of these warrants were as follows:
		October 31,	April 30,
		2013	2013
	Expected term in years	2.4 & 4.2	2.9 & 4.7
	Risk-free interest rates	0.5% & 1.1%	0.30%
	Volatility	91% & 107%	95% & 98%
	Dividend yield	0%	0%

Fair_Value_Tables

Fair Value (Tables)	6 Months Ended
	Oct. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	'
	The following table presents information about our warrant liability, which was our only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) as of October 31, 2013 (in thousands):
	Balance, May 1, 2013	$	-1,046
	Transfers to (from) Level 3		-
	Total gains (losses) included in earnings		-2,048
	Purchases, issuances and settlements, net		-
	Balance, October 31, 2013	$	-3,094

Business_Segment_Information_T

Business Segment Information (Tables)	6 Months Ended
	Oct. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	The following tables summarize, for the periods indicated, operating results by business segment (in thousands):
	Three Months Ended October 31, 2013	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Corporate
		Solutions		Solutions		Overhead
		(POS)		(TOS)
	Net revenue	$	623	$	1,760	$	-	$	2,383
	Direct cost of services		-726		-696		-		-1,422
	Sales and marketing costs		-423		-213		-		-636
	Other operating expenses		-		-673		-877		-1,550
	Stock- based compensation expense (1)		-				-476		-476
	Segment profit (loss)	$	-526	$	178	$	-1,353	$	-1,701
	Three Months Ended October 31, 2012	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Corporate
		Solutions		Solutions		Overhead
		(POS)		(TOS)
	Net revenue	$	459	$	999	$	-	$	1,458
	Direct cost of services		-576		-471		-		-1,047
	Sales and marketing costs		-378		-241		-		-619
	Other operating expenses		-		-433		-651		-1,084
	Stock- based compensation expense (1)		-		-		-624		-624
	Segment profit (loss)	$	-495	$	-146	$	-1,275	$	-1,916
	Six Months Ended October 31, 2013	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Corporate
		Solutions		Solutions		Overhead
		(POS)		(TOS)
	Net revenue	$	1,245	$	4,158	$	-	$	5,403
	Direct cost of services		-1,470		-1,566		-		-3,036
	Sales and marketing costs		-754		-460		-		-1,214
	Other operating expenses		-		-1,063		-1,534		-2,597
	Stock- based compensation expense (1)		-		-		-1,028		-1,028
	Segment profit (loss)	$	-979	$	1,069	$	-2,562	$	-2,472
	Six Months Ended October 31, 2012	Personalized		Translational		Unallocated		Consolidated
		Oncology		Oncology		Corporate
		Solutions		Solutions		Overhead
		(POS)		(TOS)
	Net revenue	$	1,377	$	2,187	$	-	$	3,564
	Direct cost of services		-1,293		-1,162		-		-2,455
	Sales and marketing costs		-814		-432		-		-1,246
	Other operating expenses		-		-794		-1,221		-2,015
	Stock- based compensation expense (1)		-		-		-1,364		-1,364
	Segment profit (loss)	$	-730	$	-201	$	-2,585	$	-3,516
	(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

Organization_Use_of_Estimates_2

Organization, Use of Estimates and Basis of Presentation (Details)	6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Common stock equivalents	18,750,622	16,060,622
Employee Stock Option [Member]	'	'
Common stock equivalents	15,473,955	14,643,955
Warrant [Member]	'	'
Common stock equivalents	3,276,667	1,416,667

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Oct. 31, 2013	Apr. 30, 2013
In Thousands, unless otherwise specified
Furniture and fixtures	$59	$59
Computer equipment and software	620	549
Laboratory equipment	185	179
Leasehold improvements	2	2
Total property and equipment	866	789
Less: Accumulated depreciation	-479	-375
Property and equipment, net	$387	$414

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Depreciation	$53	$49	$102	$103

ShareBased_Payments_Details

Share-Based Payments (Details) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Stock-based compensation expense	$476	$624	$1,028	$1,364
General and Administrative Expense [Member]	'	'	'	'
Stock-based compensation expense	401	550	820	1,119
Selling and Marketing Expense [Member]	'	'	'	'
Stock-based compensation expense	63	61	126	143
Research and Development Expense [Member]	'	'	'	'
Stock-based compensation expense	3	3	16	29
Translational Oncology Solutions Cost of Sales [Member]	'	'	'	'
Stock-based compensation expense	3	4	11	12
Personalized Oncology Solutions Cost of Sales [Member]	'	'	'	'
Stock-based compensation expense	$6	$6	$55	$61

ShareBased_Payments_Details_1

Share-Based Payments (Details 1)	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Expected term in years	'6 years	'6 years	'6 years	'6 years
Risk-free interest rates	'	0.90%	'	'
Risk-free interest rates Minimum	1.13%	'	1.13%	0.80%
Risk-free interest rates Maximum	2.41%	'	2.41%	0.90%
Volatility Minimum	97.90%	99.00%	97.90%	99.00%
Volatility Maximum	101.40%	100.00%	101.40%	100.00%
Dividend yield	0.00%	0.00%	0.00%	0.00%

ShareBased_Payments_Details_2

Share-Based Payments (Details 2) (USD $)	6 Months Ended	12 Months Ended
	Oct. 31, 2013	Apr. 30, 2013
Outstanding, Beginning Balance	13,890,205	'
Granted	1,645,000	'
Exercised	-15,000	'
Forfeited	-20,000	'
Expired	-26,250	'
Outstanding, Ending Balance	15,473,955	13,890,205
Vested and expected to vest as of October 31, 2013	15,473,955	'
Exercisable as of October 31, 2013	13,529,162	'
Weighted Average Exercise Price, Outstanding, Beginning Balance	$0.85	'
Weighted Average Exercise Price, Granted	$1.18	'
Weighted Average Exercise Price, Exercised	$0.62	'
Weighted Average Exercise Price, Forfeited	$0.50	'
Weighted Average Exercise Price, Expired	$0.75	'
Weighted Average Exercise Price, Outstanding, Ending Balance	$0.89	$0.85
Weighted Average Exercise Price, Vested and expected to vest	$0.89	'
Weighted Average Exercise Price, Exercisable	$0.85	'
Weighted Average Remaining Contractual Term, Outstanding (in years)	'7 years	'6 years 9 months 18 days
Weighted Average Remaining Contractual Life (Years), Granted	'9 years 9 months 18 days	'
Vested and expected to vest as of October 31, 2013(in Years)	'6 years 9 months 18 days	'
Weighted Average Remaining Contractual Term, Exercisable (in years)	'6 years 6 months	'
Aggregate Intrinsic Value, Outstanding, Beginning Balance	$89,000	'
Aggregate Intrinsic Value, Granted	237,000	'
Aggregate Intrinsic Value, Outstanding, Ending Balance	6,290,000	89,000
Aggregate Intrinsic Value, Vested and expected to vest	6,290,000	'
Aggregate Intrinsic Value, Exercisable	$2,703,000	'
Non-Employees [Member]	'	'
Outstanding, Beginning Balance	765,000	'
Granted	0	'
Exercised	0	'
Forfeited	0	'
Expired	0	'
Outstanding, Ending Balance	765,000	'
Vested and expected to vest as of October 31, 2013	765,000	'
Exercisable as of October 31, 2013	514,792	'
Directors and Employees [Member]	'	'
Outstanding, Beginning Balance	13,125,205	'
Granted	1,645,000	'
Exercised	-15,000	'
Forfeited	-20,000	'
Expired	-26,250	'
Outstanding, Ending Balance	14,708,955	'
Vested and expected to vest as of October 31, 2013	14,708,955	'
Exercisable as of October 31, 2013	13,014,370	'

ShareBased_Payments_Details_3

Share-Based Payments (Details 3) (Restricted Stock [Member], USD $)	6 Months Ended
	Oct. 31, 2013
Restricted Stock [Member]	'
Number of Shares, Beginning Balance	50,000,000
Shares, Granted	0
Shares, Vested	-50,000,000
Shares, Forfeited	0
Shares, Expired	0
Number of Shares, Ending Balance	0
Weighted Average Grant Date Fair Value Per Share, Nonvested, Beginning Balance	$0.30
Weighted Average Grant Date Fair Value Per Share, Granted	$0
Weighted Average Grant Date Fair Value Per Share, Vested	$0.30
Weighted Average Grant Date Fair Value Per Share, Forfeited	$0
Weighted Average Grant Date Fair Value Per Share, Expired	$0
Weighted Average Grant Date Fair Value Per Share, Nonvested, Ending Balance	$0

ShareBased_Payments_Details_4

Share-Based Payments (Details 4) (Warrant [Member], USD $)	6 Months Ended	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Oct. 31, 2013	Apr. 30, 2013
Warrant [Member]	'	'
Number of Shares, Beginning Balance	3,276,667	'
Number of Shares, Granted	0	'
Number of Shares, Exercised	0	'
Number of Shares, Expired	0	'
Number of Shares, Ending Balance	3,276,667	3,276,667
Weighted Average Exercise Price, Beginning Balance	$0.61	'
Weighted Average Exercise Price, Granted	$0	'
Weighted Average Exercise Price, Exercised	$0	'
Weighted Average Exercise Price, Expired	$0	'
Weighted Average Exercise Price, Ending Balance	$0.61	$0.61
Weighted Average Remaining Contractual Life (Years)	'3 years 4 months 24 days	'3 years 10 months 24 days
Aggregate Intrinsic Value, Beginning Balance	$0	'
Aggregate Intrinsic Value, Ending Balance	$2,215,967	$0

ShareBased_Payments_Details_Te

Share-Based Payments (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012	Oct. 31, 2013	Oct. 31, 2012
Share-based Compensation, Total	$476,000	$624,000	$1,028,000	$1,364,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$1.06	$0.26	$0.94	$0.52
Share-based Compensation Arrangement by Share-based Payment Award, Vesting Period, Fair Value	'	'	$7,500	$11,000
Class of Warrant or Right, Outstanding	3,276,667	'	3,276,667	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	1,645,000	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	'	$1.18	'
Service Based Vesting Provisions [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	'	'	5,000,000	'
Service and Performance Based Vesting Provisions [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total	'	'	5,000,000	'
Employees [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	6,400,000	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	'	$1.23	'
Chief Executive Officer and President [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	'	'	10,000,000	'
April 2011 Private Placement [Member]	'	'	'	'
Warrants Issued During Period for Common Stock	'	'	1,266,667	'
Share-based Compensation Arrangement by Share-based Payment Award, Description	'	'	'The performance-based conditions, which had to be met prior to vesting to occur included: (i) closing of one or more financings of the Company in the aggregate amount of at least $5,000,000; (ii) bringing in new Company management; (iii) launching of personalized medicine (oncology) business; and (iv) commencing implementation of the Company’s business plan. The service-based options, like all of the Company’s service-based options, are expensed on a straight-line basis. Since the straight-line method is not available for performance or market-based share-based payments, the 5,000,000 performance-based options are being expensed on an accelerated basis.	'
January 2013 Private Placement [Member]	'	'	'	'
Warrants Issued During Period for Common Stock	'	'	1,860,000	'
Equity Instrument [Member]	'	'	'	'
Class of Warrant or Right, Outstanding	150,000	'	150,000	'

Redeemable_Common_Stock_and_St2

Redeemable Common Stock and Stock Purchase Warrants (Details) (Warrant [Member])	6 Months Ended	12 Months Ended
	Oct. 31, 2013	Apr. 30, 2013
Minimum [Member]	'	'
Expected term in years	'2 years 4 months 24 days	'2 years 10 months 24 days
Risk-free interest rates	0.50%	'
Volatility	91.00%	95.00%
Dividend yield	'	0.00%
Maximum [Member]	'	'
Expected term in years	'4 years 2 months 12 days	'4 years 8 months 12 days
Risk-free interest rates	1.10%	0.30%
Volatility	107.00%	98.00%
Dividend yield	'	0.00%

Redeemable_Common_Stock_and_St3

Redeemable Common Stock and Stock Purchase Warrants (Details Textual) (USD $)	1 Months Ended		6 Months Ended	12 Months Ended
	Jan. 28, 2013	Mar. 24, 2011	Oct. 31, 2013	Apr. 30, 2013
Stock Issued During Period, Shares, Acquisitions	18,600,000	12,533,333	'	'
Common Stock Purchase Price	$0.50	$0.75	'	'
Stock Issued During Period, Value, Share-based Compensation, Gross	$9,300,000	$9,400,000	'	'
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	500,000	500,000	'	'
Proceeds from Issuance of Common Stock and Warrants	9,100,000	'	'	'
Percentage of Cash Penalties	'	'	1.00%	'
Purchase Price Limit Percentage	'	'	10.00%	10.00%
Estimated Fair Value Of Warrants	'	'	3,094,000	1,046,000
Minimum [Member]	'	'	'	'
Warrants Exercise Price Per Share	'	'	$0.50	'
Potential Penalties Amount	'	'	50,000	'
Maximum [Member]	'	'	'	'
Warrants Exercise Price Per Share	'	'	$0.90	'
Potential Penalties Amount	'	'	130,000	'
January 2013 Private Placement [Member]	'	'	'	'
Common Stock Purchase Price	'	'	$0.50	'
Warrants Issued During Period for Common Stock	'	'	1,860,000	'
Warrants Exercise Price Per Share	'	'	$0.66	'
Percentage of Common Stock Purchased	'	'	25.00%	'
Issuance of Additional Common Shares to Investors	'	'	1,064,658	'
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value	'	'	8,800,000	'
Proceeds from Issuance of Common Stock and Warrants	'	'	9,300,000	'
Proceeds from Issuance of Warrants	'	'	400,000	'
Incremental Compensation Cost	'	'	200,000	'
Warrants and Rights Outstanding	'	'	800,000	'
April 2011 Private Placement [Member]	'	'	'	'
Common Stock Purchase Price	'	'	$0.75	'
Warrants Issued During Period for Common Stock	'	'	1,266,667	'
Warrants Exercise Price Per Share	'	'	$0.90	'
Percentage of Common Stock Purchased	'	'	25.00%	'
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value	'	'	8,200,000	'
Proceeds from Issuance of Common Stock and Warrants	'	'	9,400,000	'
Proceeds from Issuance of Warrants	'	'	900,000	'
Incremental Compensation Cost	'	'	$300,000	'

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Chief Executive Officer [Member]	'	'
Related Party Transaction, Amounts of Transaction	'	$30,000
Board of Directors Chairman [Member]	'	'
Related Party Transaction, Amounts of Transaction	75,000	73,000
Substantial Stockholders [Member]	'	'
Related Party Transaction, Amounts of Transaction	'	$3,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details Textual) (USD $)	6 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Corporate Headquarters [Member]	'	'
Lease Expiration Date	30-Apr-14	'
Operating Leases, Rent Expense	$34,000	$34,000
Laboratories and Office Space [Member]	'	'
Lease Expiration Date	30-Apr-14	'
Operating Leases, Rent Expense	43,000	33,000
Israel Office Headquarters [Member]	'	'
Lease Expiration Date	31-Jul-13	'
Operating Leases, Rent Expense	6,000	14,000
Singapore Office Headquarters in Singapore [Member]	'	'
Lease Expiration Date	31-Jan-14	'
Operating Leases, Rent Expense	$3,000	$0

Licensing_Agreements_Details_T

Licensing Agreements (Details Textual)	12 Months Ended
	Apr. 30, 2013	Apr. 30, 2013	Apr. 30, 2012
	USD ($)	CAD	CAD
License Costs	'	'	45,000
Royalty Expense	'	10,000	'
Payments to Acquire Productive Assets, Total	3,000,000	'	'
Accrued Annual Royalty Payment	'	10,000	'

Cephalon_and_Teva_Agreement_De

Cephalon and Teva Agreement (Details Textual)	1 Months Ended	6 Months Ended		12 Months Ended	1 Months Ended
	Nov. 30, 2012	Oct. 31, 2013	Oct. 31, 2012	Apr. 30, 2013	Mar. 16, 2011	Mar. 16, 2011
	USD ($)	USD ($)	USD ($)	CAD	One Compound [Member]	Second Compound [Member]
					USD ($)	USD ($)
Royalty Expense	'	'	'	10,000	$460,000	$880,000
Exercise of Options to One Time Royalty Fee	880,000	880,000	'	'	'	'
Deferred Revenue, Revenue Recognized	'	133,000	237,000	'	'	'
Deferred Revenue, Period Increase (Decrease)	'	$277,000	'	'	'	'

Fair_Value_Details

Fair Value (Details) (Fair Value, Inputs, Level 3 [Member], USD $)	6 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013
Fair Value, Inputs, Level 3 [Member]	'
Balance, May 1, 2013	($1,046)
Transfers to (from) Level 3	0
Total gains (losses) included in earnings	-2,048
Purchases, issuances and settlements, net	0
Balance, October 31, 2013	($3,094)

Fair_Value_Details_Textual

Fair Value (Details Textual) (USD $)	Oct. 31, 2013	Apr. 30, 2013
Estimated Fair Value of Warrants	$3,094,000	$1,046,000

Business_Segment_Information_D

Business Segment Information (Details) (USD $)	3 Months Ended				6 Months Ended
In Thousands, unless otherwise specified	Oct. 31, 2013		Oct. 31, 2012		Oct. 31, 2013		Oct. 31, 2012
Net revenue	$2,383		$1,458		$5,403		$3,564
Sales and marketing costs	-698		-680		-1,340		-1,389
Stock- based compensation expense	-476		-624		-1,028		-1,364
Personalized Oncology Solutions [Member]	'		'		'		'
Net revenue	623		459		1,245		1,377
Direct cost of services	-726		-576		-1,470		-1,293
Sales and marketing costs	-423		-378		-754		-814
Other operating expenses	0		0		0		0
Stock- based compensation expense	0	[1]	0	[1]	0	[1]	0	[1]
Segment profit (loss)	-526		-495		-979		-730
Translational Oncology Solutions [Member]	'		'		'		'
Net revenue	1,760		999		4,158		2,187
Direct cost of services	-696		-471		-1,566		-1,162
Sales and marketing costs	-213		-241		-460		-432
Other operating expenses	-673		-433		-1,063		-794
Stock- based compensation expense	'		0	[1]	0	[1]	0	[1]
Segment profit (loss)	178		-146		1,069		-201
Unallocated Corporate Overhead [Member]	'		'		'		'
Net revenue	0		0		0		0
Direct cost of services	0		0		0		0
Sales and marketing costs	0		0		0		0
Other operating expenses	-877		-651		-1,534		-1,221
Stock- based compensation expense	-476	[1]	-624	[1]	-1,028	[1]	-1,364	[1]
Segment profit (loss)	-1,353		-1,275		-2,562		-2,585
Consolidated [Member]	'		'		'		'
Net revenue	2,383		1,458		5,403		3,564
Direct cost of services	-1,422		-1,047		-3,036		-2,455
Sales and marketing costs	-636		-619		-1,214		-1,246
Other operating expenses	-1,550		-1,084		-2,597		-2,015
Stock- based compensation expense	-476	[1]	-624	[1]	-1,028	[1]	-1,364	[1]
Segment profit (loss)	($1,701)		($1,916)		($2,472)		($3,516)
[1]	Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	6 Months Ended
	Oct. 31, 2013
Subsequent Event [Member]	'
License Agreement Aggregate Payment	$1,875,000
License Agreement Due Upon Execution	937,500
License Agreement Paid Upon Successful Delivery	$937,500